Liraglutide (GLP-1)

Both are GLP-1 receptor agonists but differ in duration, efficacy, and dosing. Liraglutide (C16 palmitate modification) achieves 13-hour half-life requiring daily injection. Semaglutide (C18 fatty diacid modification) achieves 7-day half-life allowing weekly injection. For weight loss: semaglutide 2.4 mg weekly achieves approximately 15–17% body weight reduction vs. liraglutide 3.0 mg daily at approximately 8%. For HbA1c reduction: semaglutide achieves approximately 1.5–2.0% vs. liraglutide at 1.0–1.5%. Liraglutide has the longer clinical record (approved 2010 vs. 2021 for Wegovy); semaglutide has the superior efficacy profile in direct comparisons. Liraglutide retains some advantages: pediatric obesity approval (age 12+) and longer-term post-market safety surveillance.

Both contain liraglutide but are dose-optimized for different indications. Victoza (0.6–1.8 mg/day SC) is FDA-approved for type 2 diabetes and cardiovascular risk reduction in T2D—at these doses the primary effects are glycemic control with modest weight loss (~3–5 kg). Saxenda (3.0 mg/day SC) is approved for chronic weight management in adults with BMI ≥30, or ≥27 with weight-related comorbidities, and in adolescents (12+) with obesity—the higher dose maximizes central appetite suppression for weight management as the primary goal.

LEADER (2016; PMID: 27295427; N=9,340; median follow-up 3.8 years) was the first large RCT to demonstrate cardiovascular mortality benefit from any GLP-1 agonist: 22% reduction in cardiovascular death (HR 0.78, 95% CI 0.66–0.93) and 13% reduction in 3-point MACE. LEADER also showed 22% reduction in kidney disease progression—an early indication of the renal protection benefits now recognized across the GLP-1 agonist class. This trial transformed diabetes prescribing toward drugs with proven cardiovascular benefit and preceded the FDA's addition of a CV risk reduction indication for liraglutide.

Yes, liraglutide retains several clinical niches. It has the longest post-market safety record (14+ years), which matters for long-term safety comparisons. It is the only GLP-1 agonist with pediatric obesity approval for ages 12+. Some patients who cannot tolerate semaglutide's GI side effects tolerate daily liraglutide better (smoother plasma level curve vs. weekly bolus). Generic liraglutide may become available before generic semaglutide. Cost differences and insurance formulary placement also drive selection in price-sensitive markets.

The LEADER trial included pre-specified renal outcomes and showed liraglutide reduced composite kidney disease progression (new macroalbuminuria, doubling of serum creatinine, ESRD, or renal death) by 22% vs. placebo. Renal benefits are attributed to: hemodynamic effects (renal vasodilation, reduced glomerular pressure), anti-inflammatory effects, reduction of albuminuria, and indirect benefits via improved glycemic and blood pressure control. These renal findings established the GLP-1 agonist class as kidney-protective and contributed to updated ADA guidance recommending GLP-1 agonists for T2D patients with CKD regardless of HbA1c level.

Like all GLP-1 agonists, liraglutide caused dose-dependent C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rodent studies at clinically relevant exposures. The FDA therefore contraindicated GLP-1 agonists (including liraglutide) in patients with personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). However, post-market surveillance across millions of patients and 14+ years of liraglutide use has not demonstrated a definitive increased MTC risk in humans—the mechanistic difference being that rodents (but not humans) have abundant GLP-1 receptors on thyroid C-cells. The black box warning remains as a precaution, not as confirmation of human risk.

Saxenda is initiated at 0.6 mg/day subcutaneously for 1 week to minimize GI side effects, then increased by 0.6 mg/week until reaching the maintenance dose of 3.0 mg/day at week 5. If patients cannot tolerate 3.0 mg, they may try 2.4 mg as a lower maintenance dose. Effectiveness should be assessed at 16 weeks: if less than 4% body weight has been lost, discontinuation is recommended because this population is unlikely to achieve meaningful long-term benefit. The injection site is rotated among the abdomen, thigh, or upper arm.

Liraglutide represented a substantial advance over the pre-2010 anti-obesity pharmacology landscape. Prior approved medications (orlistat, phentermine/topiramate) achieved 5–8% weight loss with significant side effects. Liraglutide at 3 mg achieves approximately 8% weight loss in clinical trials, but more importantly demonstrated the first cardiovascular safety and benefit profile in a long-term cardiovascular outcomes trial—a requirement the FDA now imposes on new anti-obesity drugs. This established the GLP-1 agonist class as the foundation of modern pharmacological obesity treatment, paving the way for semaglutide and tirzepatide's even greater efficacy.